Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual ...

Any forecast of European patent trends for the year ahead should start in Germany, the centre of gravity for patent ...

Selecting the right residential proxy provider in 2026 depends on how well the service aligns with your operational ...

Administrators from Leonard Curtis have revealed they are in "negotiations with several parties" about the potential sale of the business and assets of collapsed engineering ...

Shifting from Proprietary LLMs to Secure, Cost-Effective Enterprise Infrastructure" report has been added to ResearchAndMarkets.com's offering. The current enterprise landscape is at a critical ...

Company expands beyond smart locks with new hardware and software designed to simplify access, security, and short-term ...

PayerSync(TM) launch, security milestones, and new partnerships, including Fiserv/Clover and SKYGEN underscore Rectangle Health's leadership in simplifying healthcare payments for providers and payers ...

Increased Equity Investment in Altris Clarios has deepened its investment in Altris to accelerate product development and secure a resilient European supply chain for sodium-ion technology. The JDA ...

Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and ...

The UK’s fascinating inquiry into AI training and copyright continues. But is anyone listening? They should be.

Newron Pharmaceuticals expands IP portfolio for evenamide with new European Union composition of matter patent: Milan, Italy Thursday, January 8, 2026, 14:00 Hrs [IST] Newron Phar ...

Hoth Therapeutics expands oncology pipeline with dual patent filings establishing novel oncology dermatology IP platform: New York Saturday, January 3, 2026, 16:00 Hrs [IST] Hoth ...